Table 3 Analysis of anthracycline sub-groups (AC60, FEC75 and FAC50) homogeneity (test Pearson Khi2)
From: Concurrent chemoradiotherapy in adjuvant treatment of breast cancer
Patients characteristics | Group FEC75 [n = 23] No (%) | Group FAC50 [n = 20] No (%) | Group AC60 [n = 57] No (%) | p value |
|---|---|---|---|---|
Age | ||||
   <40 | 8 (34.8%) | 7 (35%) | 14 (24.6%) | 0.53 |
   ≥40 | 15 (65.2%) | 13 (65%) | 43 (75.4%) |  |
Menopausal status | ||||
   No | 20 (90.9%) | 14 (77.8%) | 35 (66%) | 0.075 |
   Yes | 2 (9.1%) | 4 (22.2%) | 18 (34%) |  |
Side | ||||
   Right | 14 (60.9%) | 7 (35%) | 24 (42.1%) | 0.188 |
   Left | 9 (39.1%) | 13 (65%) | 33 (57.9%) |  |
Surgery | ||||
   Mastectomy | 5 (21.7%) | 5 (25%) | 8 (14%) | 0.457 |
   Conservative | 18 (78.3%) | 15 (75%) | 49 (86%) |  |
Histology | ||||
   CCI | 20 (95.2%) | 19 (95%) | 52 (94.5%) | 0.992 |
   CLI | 1 (4.8%) | 1 (5%) | 3 (5.5%) |  |
SBR | ||||
   I | 0 | 1 (5%) | 4 (7.1%) | 0.31 |
   II | 14 (70%) | 10 (50%) | 39 (69.6%) |  |
   III | 6 (30%) | 9 (45%) | 13 (23.2%) |  |
Hormonal receptors | ||||
ER | ||||
   Positive | 18 (81.8%) | 11 (55%) | 42 (76.4%) | 0.106 |
   Negative | 4 (18.2%) | 9 (45%) | 13 (23.6%) |  |
PR | ||||
   Positive | 17 (77.3%) | 7 (35%) | 31 (57.4%) | 0.022 |
   Negative | 5 (22.7%) | 13 (65%) | 23 (42.6%) |  |
Tumour | ||||
   pT1 | 6 (26.1%) | 1 (5%) | 9 (16.1%) | 0.514 |
   pT2 | 10 (43.5%) | 13 (65%) | 32 (57.1%) |  |
   pT3 | 7 (30.4%) | 5 (25%) | 13 (23.2%) |  |
   pT4 | 0 | 1 (5%) | 2 (3.6%) |  |
pN, axillary | ||||
   pN0 | 6 (26.1%) | 3 (15%) | 9 (15.8%) | 0.807 |
   pN1 | 4 (17.4%) | 4 (20%) | 15 (26.3%) |  |
   pN2 | 7 (30.4%) | 5 (25%) | 18 (31.6%%) |  |
   pN3 | 6 (26.1%) | 8 (40%) | 15 (26.3%%) |  |